National / Demand for trial of Covaccine booster dose on children of 2-18 years, Bharat Biotech seeks permission from DCGI

Zoom News : May 04, 2022, 07:52 PM
New Delhi: Bharat Biotech has sought permission from the drug regulator for Phase II/3rd trial of Covaxin Booster Dose in children in the age group of 2 years to 18 years. Sources gave this information to 'PTI-Bhasha'. Currently, a precautionary dose of Covaccine and Covishield is being given to people 18 years of age and older who have completed 9 months of receiving the second dose.

A source familiar with the development told PTI, "The Hyderabad-based company has applied to the Drug Controller General of India (DCGI) on April 29 to allow a booster dose of Covaccine on children aged two to 18 years. This study will be done at 6 locations including All India Institute of Medical Sciences (AIIMS), Delhi and Patna.

India began giving a precautionary dose of the vaccine to health workers and frontline workers and people over the age of 60 with other diseases from January 10 this year. In March, all people aged 60 and over were deemed eligible for preventive doses by eliminating the co-morbidity condition.

India on April 10 allowed precautionary doses for all persons above the age of 18 years at private vaccination centres. Currently, the Corbevax vaccine is being administered to children between the ages of 12 and 14 to protect against the corona virus.

Currently, two Kovid-19 vaccines are being administered to children above 12 years of age in India. The first phase of immunization of children in the country began on January 3 this year, with the announcement of COVID vaccination for children in the age group of 15-18 years, which would later be extended to cover children above 12 years of age from March 16. expanded to.